Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.61 |
| ▸ | CMA1 | P23946 | 2/20 | 0.61 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.53 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | HTR5A | P47898 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.46 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13529011 | 0.87 | CRBN (0.61) | AHRCMA1EIF2AK2PDK2CRBN | |
| SCHEMBL433708 | 0.84 | AHR (0.61) | AHRCMA1PDK2MMP12EPHX2 | |
| SCHEMBL11927572 | 0.83 | HTR5A (0.53) | AHRCMA1EIF2AK2MMP12SMN1; SMN2 | |
| SCHEMBL1025832 | 0.82 | CA9 (0.62) | MMP12CRBNSMN1; SMN2EPHX2HTR5A | |
| SCHEMBL29754317 | 0.82 | CA9 (0.62) | MMP12CRBNSMN1; SMN2EPHX2HTR5A | |
| SCHEMBL10274620 | 0.82 | EPHX2 (0.55) | AHRMMP12RAB9ASMN1; SMN2EPHX2 | |
| SCHEMBL8265611 | 0.81 | CRBN (0.61) | AHRCMA1EIF2AK2PDK2CRBN | |
| SCHEMBL15601784 | 0.80 | PKM (0.48) | AHRCMA1EIF2AK2PDK2MMP12 | |
| SCHEMBL7428888 | 0.79 | MAPT (0.58) | AHRCMA1MMP12CRBNRAB9A | |
| SCHEMBL15241838 | 0.79 | MAPT (0.53) | AHRCMA1MMP12CRBNRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | claimed |
| CN-118510517-A | Therapeutically effective combination of FLT3 inhibitor and BCL-2 inhibitor for the treatment of acute myeloid leukemia | 韩美药品有限公司 | 2024-08-16 | — | — | CN | claimed |
| CN-112469715-B | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2024-06-11 | — | — | CN | claimed |
| CN-116693506-A | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2023-09-05 | — | — | CN | claimed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | claimed |
| EP-4630122-A1 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | Aptose Biosciences Inc. (CA) | 2025-10-15 | — | — | EP | disclosed |
| US-12433867-B2 | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | HANMI PHARM. CO., LTD. (KR) | 2025-10-07 | — | — | US | disclosed |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| WO-2024124199-A9 | METHODS FOR TREATING PATIENTS WITH HEMATOLOGIC MALIGNANCIES | APTOSE BIOSCIENCES INC. (CA) | 2025-06-12 | — | — | WO | disclosed |
| CN-116693506-B | Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising the same | 韩美药品株式会社 | 2024-11-26 | — | — | CN | disclosed |
| CN-118510517-A | Therapeutically effective combination of FLT3 inhibitor and BCL-2 inhibitor for the treatment of acute myeloid leukemia | 韩美药品有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-5464861-A | Anticarcinogenic agents | WARNER-LAMBERT (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0654024-A1 | 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003427-A1 | 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1994-02-17 | — | — | WO | disclosed |
| EP-0208510-B1 | 1-SUBSTITUTED OXINDOLE-3-CARBOXAMINES AS ANTIINFLAMMATORY AND ANALGESIC AGENTS | PFIZER INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| US-4791129-A | RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4725616-A | ANTIARTHRITIC AGENTS | PFIZER INC. (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0208510-A2 | 1-Substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents | PFIZER INC. (US) | 1987-01-14 | — | — | EP | disclosed |
| CN-86105309-A | Oxindole-3-carbonyl amines the compound that replaces as the 1-of anti-inflammatory and anodyne | — | 1987-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | AHR 1448/4885CMA1 4370/4885EIF2AK2 1219/4885 |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | FLT3, MCL1, CSF3R | AHR 908/4885CMA1 3860/4885EIF2AK2 2698/4885 |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | FLT3, MCL1, CSF3R | AHR 908/4885CMA1 3860/4885EIF2AK2 2698/4885 |
| US-12433867-B2 | Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia | FLT3, MCL1, HGFAC | AHR 361/4885CMA1 3788/4885EIF2AK2 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.